Loading stock data…
BIIB
$196.60-2.50 (-1.26%)
Market OpenUpdated 1:29 PM EDT
Biogen Inc.
Historical Price
Price (Candle)
50-Day SMA
200-Day SMA
Whystock Brain
The Narrative
Biogen Inc. in the Healthcare sector is trading at $196.60 with a market capitalization of $28.9B. Wall Street consensus targets $220.63 (30 analysts), implying a +12.2% move over the next 12 months. The stock is currently near its 52-week high of $205.97, remaining 13.8% above its 200-day moving average. On fundamentals, Piotroski 5/9 shows mixed financial quality, Altman Z in the safe zone. The Whystock Score of 80/100 reflects bullish alignment across trend, valuation and analyst targets.
Ecosystem Influences
Sell-side targets imply +12.2% upside over 12 months
Long-term trend bullish (price vs 200-day SMA)
Macro-economic sensitivity to interest rate and inflation shifts
Quarterly Financials
| Metric (USD) | Q1 2026 | Q4 2025 | Q3 2025 | Q2 2025 | Q1 2025 |
|---|---|---|---|---|---|
| Total Revenue | $2.48B↑ | $2.28B↓ | $2.53B↓ | $2.65B↑ | $2.43B |
| Gross Profit | $1.82B↑ | $1.78B↓ | $1.86B↓ | $2.04B↑ | $1.80B |
| Operating Income | $459.80M↑ | $385.50M↓ | $606.50M↓ | $851.80M↑ | $625.20M |
| Net Income | $319.50M↑ | -$48.90M↓ | $466.50M↓ | $634.80M↑ | $240.50M |
Peer Comparison
JNJUNHPFE
Fundamentals
Biogen Inc. discovers, develops, manufactures, and delivers therapies in the United States, Europe, Germany, Asia, and internationally. The company provides TECFIDERA, VUMERITY, AVONEX, PLEGRIDY, and TYSABRI for multiple sclerosis (MS); SPINRAZA for ...
Market Cap
Total dollar market value of a company's outstanding shares of stock (Price * Shares).
$28.93B
P/E Ratio
Priced for growth. Investors expect sustained double-digit expansion.
21.05
Beta
Defensive asset. Lower volatility than the S&P 500.
0.20
Div Yield
Low to zero yield. Return is entirely dependent on price appreciation.
0.00%
ROE
Average efficiency. Growth may require heavy reinvestment.
7.36%
Volume
Today's trading volume
287,484
Recent News
1 Cash-Producing Stock with Impressive Fundamentals and 2 We Find Risky
While strong cash flow is a key indicator of stability, it doesn’t always translate to superior returns. Some cash-heavy businesses struggle with inefficient spending, slowing demand, or weak competitive positioning.
How Is Biogen’s Stock Performance Compared to Other Biotech Stocks?
Biogen has recently outperformed its industry peers, and analysts remain reasonably upbeat about the stock’s prospects.
Should Biogen’s (BIIB) New SMA Breakthrough and Lupus Data Prompt a Fresh Look From Investors?
In early June 2026, Biogen reported that the FDA granted Breakthrough Therapy Designation to its investigational SMA treatment salanersen, while also, alongside UCB, presenting additional positive Phase 3 data for lupus candidate dapirolizumab pegol at the EULAR 2026 Congress. Together, these developments highlight Biogen’s expanding late-stage pipeline in severe neuromuscular and autoimmune diseases, with salanersen’s once-yearly dosing and dapirolizumab pegol’s steroid-sparing potential...
A Look At Biogen (BIIB) Valuation After New Breakthrough SMA Nod And Positive Lupus Phase 3 Data
Biogen (BIIB) is back in focus after the FDA granted Breakthrough Therapy Designation to its spinal muscular atrophy candidate salanersen, while fresh Phase 3 lupus data with partner UCB highlighted dapirolizumab pegol’s clinical profile. See our latest analysis for Biogen. Biogen’s recent FDA breakthrough designation for salanersen and fresh lupus data arrive as the share price trades at US$196.45, with a 90-day share price return of 6.26% and a 1-year total shareholder return of 50.70%,...
BIIB's Next-Gen SMA Therapy Salanersen Wins FDA's Breakthrough Tag
Biogen's Salanersen secures FDA Breakthrough Therapy designation for SMA after phase Ib data showed motor gains and supports once-yearly dosing.